Clinical Trials
> Gastric/Esophageal Cancer

EMR 100070-008

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

EMR 100070-007

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718c) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction.